Finasteride 5mg 30 tablets

Composition
active ingredient: finasteride;

1 tablet contains finasteride 5 mg;

excipients: lactose monohydrate, corn starch, povidone 30, sodium starch glycolate (type A), docusate sodium, magnesium stearate, hypromellose 2910/5, macrogol 6000, talc, titanium dioxide (E 171), simethicone emulsion SE4, iron oxide yellow (E 172).

Indications
Treatment and control of benign prostatic hyperplasia (BPH) in patients with an enlarged prostate gland to:

reduce the size (regression) of the enlarged gland, improve urine flow, and reduce symptoms associated with BPH;
reduce the risk of acute urinary retention and the need for surgery, including transurethral resection of the prostate and prostatectomy.

Method of administration and dosage
The recommended dose is 1 tablet of 5 mg 1 time per day, regardless of meals.

Finasteride can be used as monotherapy or in combination with the alpha-blocker doxazosin.

The duration of treatment is determined by the doctor individually. Despite the fact that improvement in symptoms may be observed earlier, at least six months of taking the drug are necessary to assess the effectiveness of the action, after which treatment should be continued. The risk of acute urinary retention decreases within four months after the end of treatment.

For patients with renal failure of varying severity (with a decrease in creatinine clearance to 0.9 ml/min), dose adjustment is not required, since pharmacokinetic studies have not revealed any changes in the distribution of finasteride.

There are no data on the use of the drug in patients with impaired liver function.

For elderly patients, dose adjustment is not required.

Do not use in children.